Market Update (NYSE:BMY): Europe pushes back verdict on Bristol immune system cancer drug

[Reuters] – European regulators have postponed a decision on whether to recommend approval of a closely watched Bristol-Myers Squibb drug that helps the immune system fight cancer, officials said on Friday. Nivolumab, which . . . → Read More: Market Update (NYSE:BMY): Europe pushes back verdict on Bristol immune system cancer drug Similar Articles: Stock Update (NYSE:BMY): Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy Market Update (NYSE:BMY): Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival